{
    "symbol": "MDXG",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-02 22:32:02",
    "content": " Before we begin, I would like to remind you that our comments today will include forward-looking statements, including statements regarding future sales growth, future margin, expected market sizes for our products and potential time lines for clinical trials and FDA submissions and reviews. Looking to revenue outlook, we expect fourth quarter net sales to be between $73 million and $76 million, which reflects year-over-year growth in a range of 8% to 15%. For the full year 2022, this would result in net sales between $266 million and $269 million or growth of 11% to 12% over 2021 net sales of our continuing portfolio of products."
}